← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Closed-loop transcranial focused ultrasound to restore hippo (PVALB) — 1.00 Closed-loop tACS targeting EC-II SST interneurons to block t (SST) — 1.00 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 1.00 Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 1.00 Metabolic Reprogramming to Reverse Senescence (SIRT1,PGC1A,NAMPT) — 1.00 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.99 Closed-loop tACS targeting EC-II PV interneurons to suppress (PVALB) — 0.99 SASP Modulation Rather Than Cell Elimination (NFKB1,IL1B,BDNF) — 0.98 Beta-frequency entrainment therapy targeting PV interneuron- (SST) — 0.98 LRP1-Dependent Tau Uptake Disruption (LRP1) — 0.98 Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte (SST, SSTR1, SSTR2) — 0.97 Closed-loop tACS targeting EC-II parvalbumin interneurons to (PVALB) — 0.97 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.94 Dual-Receptor Antibody Shuttling (?) — 0.94 PLCG2 Allosteric Modulation as a Precision Therapeutic for T (PLCG2) — 0.94 SASP-Driven Microglial Metabolic Reprogramming in Synaptic P (HK2/PFKFB3) — 0.93 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.93 Closed-loop transcranial alternating current stimulation to (SST) — 0.93 Autophagy-Senescence Axis Therapeutic Window (ATG7,BCL2,BCL2L1) — 0.92 Closed-loop tACS targeting entorhinal cortex layer II SST in (SST) — 0.92 Palmitoylethanolamide-Based Endocannabinoid Therapy (PPARA) — 0.92 Closed-loop focused ultrasound targeting CA1 PV interneurons (PVALB) — 0.92 TREM2-mediated microglial tau clearance enhancement (TREM2) — 0.92 Chromatin Remodeling-Mediated Nutrient Sensing Restoration (SMARCA4) — 0.91 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.91 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Alpha-gamma cross-frequency coupling enhancement to restore (SST) — 0.91 TREM2-ASM Crosstalk in Microglial Lysosomal Senescence (SMPD1) — 0.91 sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy (?) — 0.91
Add
|
× Test: TREM2 enhances amyl
- · - · -
Composite 0.712
Price $0.70
Evidence For 1
Evidence Against 0
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Test: TREM2 enhances amyloid c Mechanistic 0.500 Evidence 0.000 Novelty 0.000 Feasibility 0.000 Impact 0.000 Druggability 0.000 Safety 0.000 Competition 0.000 Data 0.500 Reproducible 0.000
Evidence Test: TREM2 enhances amyloid clearance Supporting Evidence Facilitating microglial phagocytosis by which Jiawei Xionggui Decoction alleviates cognitive impairment via TREM2-mediat PMID:40754372 Chin J Nat Med 2025 Price History Overlay